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Clinical PerspectiveWhat Is New?Patients with right ventricular outflow tract lesions of moderate severity have a low risk of cardiovascular complications during pregnancy, and there is no association between the hemodynamic severity of valve lesion and clinical outcomes during pregnancy.What Are the Clinical Implications?As a result, asymptomatic patients with right ventricular outflow tract lesions who do not otherwise meet criteria for intervention and are contemplating pregnancy can be managed conservatively without need for prophylactic intervention before pregnancy.

Introduction {#jah34058-sec-0008}
============

Because of continuing improvements in medical, transcatheter, and surgical therapies over the past several decades, the adult congenital heart disease (ACHD) population has grown significantly.[1](#jah34058-bib-0001){ref-type="ref"}, [2](#jah34058-bib-0002){ref-type="ref"} More than 85% of children with congenital heart disease undergoing surgical or transcatheter interventions in the current era will survive into adulthood, with future pregnancy anticipated in some of the female patients.[1](#jah34058-bib-0001){ref-type="ref"}, [2](#jah34058-bib-0002){ref-type="ref"}, [3](#jah34058-bib-0003){ref-type="ref"}, [4](#jah34058-bib-0004){ref-type="ref"} The complex antepartum, intrapartum, and postpartum hemodynamic changes may result in life‐threatening complications in women with structural heart disease.[4](#jah34058-bib-0004){ref-type="ref"}, [5](#jah34058-bib-0005){ref-type="ref"} Preconceptual counseling, risk stratification, and prompt identification and treatment of complications during pregnancy are important strategies to prevent, or at least potentially reduce adverse outcomes.[4](#jah34058-bib-0004){ref-type="ref"}, [5](#jah34058-bib-0005){ref-type="ref"}, [6](#jah34058-bib-0006){ref-type="ref"}, [7](#jah34058-bib-0007){ref-type="ref"}, [8](#jah34058-bib-0008){ref-type="ref"}

Right ventricular outflow tract (RVOT) obstructive lesions account for more than two thirds of complex congenital heart disease diagnoses among newborns,[9](#jah34058-bib-0009){ref-type="ref"}, [10](#jah34058-bib-0010){ref-type="ref"} and interventions for residual or recurrent RVOT lesions account for \>20% of the procedures performed in ACHD patients.[11](#jah34058-bib-0011){ref-type="ref"} A common clinical dilemma encountered in counseling patients with isolated residual or recurrent RVOT lesions is to determine whether interventional therapy should be recommended before conception. Although several studies have proposed risk models for pregnancy‐related adverse outcomes (PRAO) in ACHD patients with RVOT lesions, the majority of these models are confounded, to a great extent, by the presence of concurrent left heart obstruction, systemic ventricular dysfunction, mechanical prosthesis, and cyanosis.[3](#jah34058-bib-0003){ref-type="ref"}, [12](#jah34058-bib-0012){ref-type="ref"}, [13](#jah34058-bib-0013){ref-type="ref"}, [14](#jah34058-bib-0014){ref-type="ref"} Consequently, at present only limited data exist regarding the risk of PRAO in women with isolated RVOT lesions,[15](#jah34058-bib-0015){ref-type="ref"} and such data will be important in deciding whether interventional therapy should be recommended before proceeding with pregnancy.

The current study was designed to address 2 key questions: (1) What is the incidence of PRAO in patients with isolated RVOT lesions? and (2) Does the presence of a hemodynamically significant RVOT lesion (RVOT‐HS) increase the risk of PRAO in this population?

Methods {#jah34058-sec-0009}
=======

Patient Selection {#jah34058-sec-0010}
-----------------

We will make data, analytic methods, and study materials available to other researchers upon request. We reviewed the Mayo Adult Congenital Heart Disease (MACHD) database and identified all women of childbearing age (age 18--50 years) with prior surgical and/or transcatheter RVOT interventions who received care during pregnancy at Mayo Clinic from January 1, 1990 through December 31, 2017. The Mayo Clinic institutional review board approved this study and waived informed consent for patients who provided research authorization. RVOT intervention was defined as surgical pulmonary valvotomy/valvectomy, transannular patch repair, surgical pulmonary valve replacement or right ventricular to pulmonary artery conduit placement, balloon pulmonary valvuloplasty, and transcatheter pulmonary valve replacement. We excluded women with significant left heart disease defined as prior mitral and/or aortic valve replacement, and significant (≥moderate) mitral, aortic, or subaortic lesions. We also excluded patients without delivery or postnatal follow‐up data.

Data Collection {#jah34058-sec-0011}
---------------

The last transthoracic echocardiogram performed within 12 months preceding conception or the first echocardiogram performed in the first trimester (when preconception echocardiogram was not available) was considered the baseline echocardiogram. Images were reviewed and hemodynamic variables collected from the baseline echocardiogram, last echocardiogram before delivery, and last echocardiogram within the study period. The severity of tricuspid regurgitation, pulmonary/conduit regurgitation, RV enlargement, and RV systolic dysfunction were graded as none/trivial, mild, mild--moderate, moderate, moderate--severe, and severe based on standard assessment by comprehensive echocardiogram.[16](#jah34058-bib-0016){ref-type="ref"}, [17](#jah34058-bib-0017){ref-type="ref"} Obstetric records and discharge summaries were reviewed to determine the occurrence of PRAO.

End Points and Definitions {#jah34058-sec-0012}
--------------------------

The primary objective was to determine the incidence of PRAO outcomes in patients with prior RVOT interventions, and compare this risk with historic data of pregnancy outcomes in adults with congenital heart disease.[3](#jah34058-bib-0003){ref-type="ref"}, [12](#jah34058-bib-0012){ref-type="ref"}, [13](#jah34058-bib-0013){ref-type="ref"}, [14](#jah34058-bib-0014){ref-type="ref"} The secondary objective was to assess the impact of RVOT‐HS lesions on PRAO in this study cohort. In order to assess the relationship between RVOT‐HS lesions and PRAO, we defined hemodynamically significant RVOT lesions as moderate pulmonary/conduit stenosis (peak continuous wave Doppler velocity ≥3 m/s) and/or ≥moderate regurgitation based on hemodynamic variables from the baseline echocardiogram.

PRAO was defined as a composite of cardiovascular, obstetric, and neonatal complications. In concordance with previous studies,[3](#jah34058-bib-0003){ref-type="ref"}, [12](#jah34058-bib-0012){ref-type="ref"}, [13](#jah34058-bib-0013){ref-type="ref"}, [14](#jah34058-bib-0014){ref-type="ref"} cardiovascular complications were defined as heart failure (pulmonary edema or peripheral edema requiring oral or intravenous diuretics), sustained atrial or ventricular arrhythmias, ischemic or hemorrhagic stroke, urgent invasive cardiac procedures during pregnancy or within 6 months after delivery, and cardiovascular death. Obstetric complications were defined as gestational hypertension (new onset of systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg), pre‐eclampsia (gestational hypertension with ≥300 mg/L proteinuria per 24‐hour sample), eclampsia (hypertension‐related seizures), hemolysis‐elevated liver enzymes--low platelets syndrome, postpartum hemorrhage (blood loss \>500 mL during vaginal delivery or \>1000 mL during cesarean section within 24 hours of delivery, which required transfusion or was accompanied by a drop in hemoglobin \>2 g/L), and noncardiac death during delivery. Neonatal complications were defined as premature birth (\<37 weeks gestation), small‐for‐gestational‐age birth weight (\<10th percentile), respiratory distress syndrome, intraventricular hemorrhage, fetal death (\>20 weeks gestation), or neonatal death (within 28 days after birth). For purposes of analysis, if a patient experienced \>1 complication in the same category, this was recorded as a single event. All pregnancy losses before 20 weeks gestation were classified as spontaneous abortion, while continuation of pregnancy beyond 20 weeks was considered completed pregnancy.

Statistical Analysis {#jah34058-sec-0013}
--------------------

Data were presented as mean±SD, median (interquartile range), or counts (%), and between‐group comparisons were performed using χ^2^ test and Fisher exact test as appropriate. The association between patient‐specific risk factors including severity of RVOT lesion and the occurrence of PRAO was assessed using a univariable Cox proportional hazards model, and expressed as hazard ratio and 95% CI. For the estimation of incidence of PRAO and the risk factors for PRAO, each pregnancy was considered a separate event. All statistical analyses were performed with JMP software (version 13.0; SAS Institute Inc, Cary, NC), and a *P*\<0.05 was considered statistically significant.

Results {#jah34058-sec-0014}
=======

Baseline Clinical and Echocardiographic Data {#jah34058-sec-0015}
--------------------------------------------

Out of 502 female patients of childbearing age with a history of RVOT interventions, 114 patients met the study inclusion criteria (Figure [1](#jah34058-fig-0001){ref-type="fig"}). The clinical and echocardiographic data at the time of initial evaluation are shown in Table [1](#jah34058-tbl-0001){ref-type="table"}. The 2 most common structural diagnoses were tetralogy of Fallot (TOF) with subpulmonic stenosis followed by valvular pulmonic stenosis. Only 16 (14%) patients had their native pulmonary valve at the time of pregnancy. The median gravidity was 1 (range: 1--7). Four of the patients required a vitamin K antagonist for paroxysmal atrial arrhythmias before conception, but none of the patients were treated with anticoagulation during pregnancy. The average number of echocardiograms performed during pregnancy was 2±1 per patient. A total of 91 (80%) patients had echocardiograms in the first trimester at mean gestational age of 9±2 weeks, 112 (98%) patients had echocardiograms in the second trimester at mean gestational age of 21±3 weeks, and 86 (75%) patients had echocardiograms in the third trimester at mean gestational age of 33±2 weeks.

![Flowchart showing cohort selection. h∕o indicates history of; LH, left heart; RVOT, right ventricle outflow tract.](JAH3-8-e011730-g001){#jah34058-fig-0001}

###### 

Clinical and Echocardiographic Data at Time of First Pregnancy

                                                            n=114
  --------------------------------------------------------- ----------
  Age at time of pregnancy, y                               26±4
  Body mass index, kg/m^2^                                  26±4
  Hypertension                                              14 (12%)
  Hyperlipidemia                                            22 (19%)
  Diabetes mellitus                                         11 (10%)
  Atrial fibrillation                                       12 (11%)
  Atrial flutter/tachycardia                                26 (23%)
  Nonsustained ventricular tachycardia                      10 (9%)
  Sustained ventricular tachycardia                         1 (1%)
  Pacemaker/defibrillator                                   2 (2%)
  Oral anticoagulation                                      4 (4%)
  Prior pregnancy                                           9 (8%)
  22q11 deletion                                            4 (4%)
  CHD diagnosis                                             
  TOF with pulmonic stenosis                                44 (39%)
  TOF with pulmonary atresia                                26 (23%)
  Pulmonary atresia with IVS                                13 (11%)
  Valvular pulmonic stenosis                                31 (27%)
  Initial RVOT intervention                                 
  Surgical valvotomy/valvectomy                             43 (38%)
  Transannular patch repair                                 40 (35%)
  Surgical PVR or RV‐PA conduit                             28 (25%)
  Balloon pulmonary valvuloplasty                           3 (3%)
  Prior palliative shunts                                   58 (51%)
  Current RVOT anatomy                                      
  Native pulmonary valve                                    16 (14%)
  Surgical bioprosthetic valve                              66 (58%)
  RV‐PA conduit                                             31 (27%)
  Transcatheter bioprosthetic valve                         1 (1%)
  Echocardiography[a](#jah34058-note-0002){ref-type="fn"}   
  RVOT hemodynamics                                         
  Peak velocity, m/s                                        2.6±0.6
  Mean gradient, mm Hg                                      18±4
  Moderate regurgitation                                    11 (15%)
  Moderate/severe regurgitation                             6 (5%)
  Severe regurgitation                                      4 (4%)
  Bioprosthetic tricuspid valve                             1 (1%)
  ≥Moderate RV enlargement                                  28 (25%)
  ≥Moderate RV systolic dysfunction                         19 (17%)
  ≥Moderate tricuspid regurgitation                         12 (11%)
  RV S'                                                     11±2
  Fractional area change, %                                 42±9
  TAPSE, mm                                                 19±4
  Tricuspid regurgitation velocity, m/s                     3.1±0.3
  Lateral E/e′                                              7±2
  LV ejection fraction, %                                   59±4
  Magnetic resonance imaging                                
  RV end‐diastolic volume index, mL/m^2^                    134±18
  RV end‐systolic volume index, mL/m^2^                     61±12
  RV ejection fraction, %                                   41±6

CHD indicates congenital heart disease; E/e′, ratio of mitral inflow early filling velocity to tissue Doppler early velocity; IVS, intact ventricular septum; LV, left ventricle; PVR, pulmonary valve replacement; RV, right ventricle; RVOT, right ventricle outflow tract; RV‐PA, right ventricle to pulmonary artery; S', tissue Doppler systolic velocity; TAPSE, tricuspid annular plane systolic excursion; TOF, tetralogy of Fallot.

The assessment of severity of regurgitation, RV enlargement, and systolic dysfunction was based on qualitative assessment.

Pregnancy and Delivery Data {#jah34058-sec-0016}
---------------------------

The 114 patients had a total of 224 pregnancies, of which 2 (0.9%) were conceived with intrauterine insemination, and 1 (0.4%) via in vitro fertilization. There were 48 (21%) cases of first trimester spontaneous abortion and 3 (1%) terminations of pregnancy.

Indications for terminations included fetal hypoplastic left heart syndrome identified at 21 weeks gestation, and heart failure with sustained ventricular tachycardia in the setting of severe tricuspid and pulmonary regurgitation at 13 weeks gestation. The third case of termination of pregnancy was for tubal pregnancy at 9 weeks gestation and tubal ligation was performed during the same procedure. The incidence of spontaneous abortion was significantly different between the disease groups: TOF--pulmonic stenosis (20/106, 19%) versus TOF--pulmonary atresia (15/36, 42%) versus pulmonary atresia with intact ventricular septum (5/20, 25%) and valvular pulmonic stenosis (8/61, 13%), *P*=0.008.

A total of 173 completed pregnancies (Table [2](#jah34058-tbl-0002){ref-type="table"}) were included in the analysis. The median gestational age at the time of delivery was 38 (35--40) weeks and median birth weight was 2965 (2065--4122) g. Apgar score was available in 116 (67%) babies and mean score was 8±1. There was 1 twin gestation, and 86 (49%) of the 174 babies were male. Delivery was by cesarean section in 26 (15%) cases; the indications were fetal distress (n=7), arrest/failure of progression of labor (n=7), fetal malpresentation (n=2), repeat (elective) cesarean section (n=6), and multiple indications (n=4).

###### 

Pregnancy Data for Completed Pregnancies

                                                                        n=173
  --------------------------------------------------------------------- -----------
  Maternal age, y                                                       29±5
  Vaginal delivery                                                      147 (85%)
  Spontaneous                                                           91
  Induced                                                               58
  Assisted second stage                                                 42 (29%)
  Forceps                                                               41
  Vacuum                                                                1
  Cesarean section                                                      26 (15%)
  CHD diagnosis[a](#jah34058-note-0004){ref-type="fn"}                  
  TOF with pulmonic stenosis                                            84 (49%)
  TOF with pulmonary atresia                                            21 (12%)
  Pulmonary atresia with IVS                                            15 (9%)
  Valvular pulmonic stenosis                                            53 (31%)
  Cardiovascular complications[a](#jah34058-note-0004){ref-type="fn"}   
  Heart failure                                                         5 (3%)
  Sustained atrial arrhythmia                                           4 (2%)
  Sustained ventricular arrhythmia                                      1 (0.6%)
  Stroke                                                                0
  Urgent cardiovascular intervention                                    0
  Cardiovascular death                                                  0
  Obstetric complications[a](#jah34058-note-0004){ref-type="fn"}        
  Pregnancy‐induced hypertension                                        4 (2%)
  Pre‐eclampsia                                                         6 (4%)
  Eclampsia                                                             0
  HELLP syndrome                                                        1 (0.6)
  Postpartum hemorrhage                                                 5 (3%)
  Noncardiac death                                                      0
  Neonatal complications[a](#jah34058-note-0004){ref-type="fn"}         
  Prematurity                                                           26 (15%)
  Small‐for‐gestational‐age birth weight                                31 (18%)
  Respiratory distress syndrome                                         12 (7%)
  Intraventricular hemorrhage                                           2 (1%)
  Fetal death                                                           0
  Neonatal death                                                        1 (0.6%)

Although 1 of the terminations of pregnancy occurred at 21 weeks, that particular pregnancy was not counted as a completed pregnancy. CHD indicates congenital heart disease; HELLP, hemolysis, elevated liver enzyme, low platelet; IVS, intact ventricular septum; TOF, tetralogy of Fallot.

All calculations based on total number of completed pregnancies (n=173).

Pregnancy‐Related Adverse Outcomes {#jah34058-sec-0017}
----------------------------------

Table [2](#jah34058-tbl-0002){ref-type="table"} shows the different cardiovascular and obstetric neonatal complications during pregnancy. The cardiovascular complications observed were heart failure and arrhythmias, and these were managed conservatively without need for hospitalization or interventions. The total counts of complications observed were 10 (4%) cardiovascular, 16 (6%) obstetric, and 75 (22%) neonatal complications (Figure [2](#jah34058-fig-0002){ref-type="fig"}). There were 3 neonates with congenital heart disease, of which 2 had TOF--pulmonary atresia and 1 coarctation of the aorta with large ventricular septal defect. In all 3 cases the maternal diagnosis was TOF--pulmonic stenosis; none of the mothers had genetic diagnosis of 22q11 deletion. One infant was diagnosed with trisomy 21 (Down syndrome) without congenital heart disease, and the maternal age was 42 years. The only neonatal death occurred in the infant who had coarctation of aorta and large ventricular septal defect and who also had multiple extracardiac congenital malformations.

![Bar graphs showing the incidence of spontaneous abortion and pregnancy‐related adverse outcomes. Data from the current study shown in blue (Egbe et al) are compared side by side to ZAHARA study[12](#jah34058-bib-0012){ref-type="ref"}; Drenthen et al[3](#jah34058-bib-0003){ref-type="ref"}; CARPREG study[13](#jah34058-bib-0013){ref-type="ref"}; and Khairy et al.[14](#jah34058-bib-0014){ref-type="ref"} \*Data about obstetric complication were unavailable in the Drenthen et al study.](JAH3-8-e011730-g002){#jah34058-fig-0002}

Hemodynamically Significant RVOT Lesions {#jah34058-sec-0018}
----------------------------------------

Of the 173 pregnancies, 38 (22%) pregnancies in 24 patients occurred in the setting of RVOT‐HS lesions as follows: severe pulmonary regurgitation (n=8, 5%), mixed moderate/severe stenosis and regurgitation (n=24, 14%), and ≥moderate pulmonary valve/conduit stenosis (n=6, 4%). Compared with the remainder of the cohort, the pregnancies that occurred in the setting of RVOT‐HS lesions experienced a similar incidence of spontaneous abortions and other PRAO (Figure [3](#jah34058-fig-0003){ref-type="fig"}). However, as an individual entity, TOF--pulmonary atresia was associated with increased rates of both spontaneous abortion (hazard ratio 2.79, 95% CI 2.33--3.17, *P*=0.001) and neonatal complications (hazard ratio 1.84, 95% CI 1.09--2.37, *P*=0.024), Table [3](#jah34058-tbl-0003){ref-type="table"}. Of the 28 pregnancies that occurred in the 26 patients with TOF--pulmonary atresia, 9 occurred in the setting of RVOT‐HS. In the subsets of patient with TOF--pulmonary atresia, there was no significant difference in the incidence of PRAO between those with RVOT‐HS versus those without RVOT‐HS (cardiac complications 5.1% versus 5.9%, *P*=0.616; obstetric complications 9.3% versus 9.5%, *P*=0.814; and neonatal complications 29% versus 28%, *P*=0.711).

![Bar graphs comparing the incidence of spontaneous abortion and pregnancy‐related adverse outcomes between patients with and without hemodynamically significant RVOT lesion. RVOT indicates right ventricle outflow tract.](JAH3-8-e011730-g003){#jah34058-fig-0003}

###### 

Univariable Risk Factors for Pregnancy‐Related Adverse Outcomes

                                                                                   Abortions           Cardiovascular      Obstetric           Neonatal
  -------------------------------------------------------------------------------- ------------------- ------------------- ------------------- -------------------
  Age \>35 y                                                                       2.14 (0.75--6.11)   1.84 (0.43--2.33)   1.98 (0.86--2.75)   1.54 (0.84--3.11)
  TOF with pulmonic stenosis                                                       1.43 (0.84--2.96)   1.02 (0.63--1.98)   1.07 (0.71--2.89)   0.97 (0.49--1.95)
  TOF with pulmonary atresia                                                       2.79 (2.33--3.17)   2.07 (0.65--5.32)   1.87 (0.78--3.94)   1.84 (1.09--2.37)
  Pulmonary atresia with IVS                                                       1.86 (0.54--3.94)   1.65 (0.87--2.68)   0.85 (0.11--4.19)   1.01 (0.44--3.82)
  Valvular pulmonic stenosis                                                       0.80 (0.46--0.97)   0.91 (0.66--1.06)   1.03 (0.67--1.98)   0.88 (0.62--1.02)
  Native pulmonary valve                                                           0.88 (0.35--1.04)   1.04 (0.42--3.76)   1.08 (0.67--2.74)   0.85 (0.33--1.97)
  Hemodynamically significant RVOT lesion[a](#jah34058-note-0006){ref-type="fn"}   1.47 (0.96--2.62)   1.21 (0.27--4.11)   1.06 (0.72--3.54)   1.65 (0.14--2.83)
  LV ejection fraction \<40%                                                       1.06 (0.74--1.92)   1.54 (0.43--2.99)   1.12 (0.57--2.87)   1.44 (0.87--3.66)
  ≥Moderate RV systolic dysfunction                                                1.75 (0.21--4.18)   1.76 (0.92--3.93)   1.18 (0.49--2.78)   1.94 (0.81--3.47)
  ≥Moderate tricuspid regurgitation                                                2.63 (0.55--6.13)   2.16 (0.98--3.87)   1.09 (0.28--4.11)   1.63 (0.71--4.16)

HR indicates hazard ratio; IVS, intact ventricular septum; LV, left ventricle; RV, right ventricle; RVOT, right ventricle outflow tract; TOF, tetralogy of Fallot.

Defined as moderate pulmonary/conduit stenosis (≥3 m/s) and/or ≥ moderate regurgitation based on hemodynamic variables from the baseline echocardiogram.

An exploratory analysis was performed to determine whether severe valve/conduit stenosis defined as peak velocity \>4 m/s was associated with PRAO. There are only 2 patients with peak velocity \>4 m/s, thereby precluding any meaningful statistical analysis. We also performed exploratory analysis to determine whether preoperative cardiac magnetic resonance imaging-- derived volumetric indices were associated with PRAO. Of the 32 patients with ≥moderate pulmonary regurgitation, cardiac magnetic resonance imaging--derived volumetric indices were available in 21 patients. Using the median right ventricular end‐diastolic volume, end‐systolic volume, and ejection fraction as cut‐off points, there was no association between cardiac magnetic resonance imaging--derived volumetric indices and occurrence of PRAO.

The mean follow‐up from first pregnancy to end of study interval was 4.3±1.4 years for the 24 patients with RVOT‐HS lesions. During this period, 7 of the 24 patients underwent pulmonary valve replacement; the other 17 patients did not experience any symptomatic deterioration, progression of RVOT lesion, or deterioration of RV function.

Discussion {#jah34058-sec-0019}
==========

In this study of 114 patients with RVOT lesions, the incidence of cardiovascular complications during pregnancy was 4%, regardless of the presence or absence of RVOT‐HS lesions. Previous work has described the incidence and risk factors for cardiovascular complications during pregnancy in patients with structural heart disease to be 8% to 20%.[3](#jah34058-bib-0003){ref-type="ref"}, [12](#jah34058-bib-0012){ref-type="ref"}, [13](#jah34058-bib-0013){ref-type="ref"}, [14](#jah34058-bib-0014){ref-type="ref"}, [18](#jah34058-bib-0018){ref-type="ref"}, [19](#jah34058-bib-0019){ref-type="ref"} The identified predictive factors are remarkably consistent, implicating systemic ventricular dysfunction, left heart obstruction, mechanical prosthesis, and cyanosis in cardiovascular complications.[12](#jah34058-bib-0012){ref-type="ref"}, [13](#jah34058-bib-0013){ref-type="ref"}, [14](#jah34058-bib-0014){ref-type="ref"}, [18](#jah34058-bib-0018){ref-type="ref"} Patients with RVOT lesions are not generally considered to be at high risk for cardiovascular events during pregnancy even though there are very limited data of outcomes in this population to support or refute this notion.[15](#jah34058-bib-0015){ref-type="ref"}

In a recent study of pregnancy outcomes in women with allograft RVOT conduits, Romeo et al[15](#jah34058-bib-0015){ref-type="ref"} reported a 6% incidence of cardiovascular complications (no deaths), but subgroup analysis of differential risk based on the severity of residual RVOT lesion (a modifiable risk factor) was not performed, perhaps because of small sample size. In addition to reporting a similar frequency of cardiovascular complications, the current study also demonstrates that the risk of cardiovascular complications remains low even in the setting of a hemodynamically significant residual RVOT lesion at the time of conception. This has profound implications for counseling on the merits of preconceptual interventional therapy for an asymptomatic patient with a RVOT‐HS lesion in anticipation of the further hemodynamic stress of pregnancy. Among the 24 patients with RVOT‐HS lesions, 11 patients went on to have multiple pregnancies (without cardiac interventions between pregnancies) without cardiovascular complications. There was no symptomatic or hemodynamically significant deterioration in the patients who did not undergo interventions during follow‐up. These findings, despite the limitations of a retrospective study, suggest that the timing of surgical or transcatheter interventions should not be influenced by future reproductive intent.

We also observed spontaneous abortions in 21% of the pregnancies in this cohort. A subgroup analysis showed that the incidence of spontaneous abortion varied by underlying diagnosis, ranging from 13% in patients with valvular pulmonic stenosis to as high as 42% in patients with TOF--pulmonary atresia. Other studies have reported spontaneous abortion in 3% to 19% of pregnancies in patients with congenital heart disease, and genetic and hemodynamic factors have been proposed as potential causes of spontaneous abortion in these patients.[12](#jah34058-bib-0012){ref-type="ref"}, [13](#jah34058-bib-0013){ref-type="ref"}, [14](#jah34058-bib-0014){ref-type="ref"}, [18](#jah34058-bib-0018){ref-type="ref"} Patients with TOF--pulmonary atresia are known to have high prevalence of genetic abnormalities including 22q11 deletion, and several studies have shown increased risk of first trimester spontaneous abortions in patients with genetic and chromosomal abnormalities.[20](#jah34058-bib-0020){ref-type="ref"}, [21](#jah34058-bib-0021){ref-type="ref"}, [22](#jah34058-bib-0022){ref-type="ref"} We speculated that genetic factors may be responsible for the particularly high occurrence of spontaneous abortions in patients with TOF--pulmonary atresia, although we cannot confirm this speculation because most of the patients did not have testing. Although hemodynamic factors have been postulated as a potential cause of spontaneous abortion in this population, we did not observe any association between abortion and severity of RVOT lesions in our cohort. We do not think that hemodynamic factors contribute significantly to spontaneous abortion because the peak hemodynamic stress of pregnancy occurs in the second and third trimesters, which is much later than the timing of spontaneous abortions that is usually in the first trimester.

We also observed neonatal complications in 22% of pregnancies, mostly because of prematurity and small‐for‐gestational age. TOF--pulmonary atresia diagnosis was associated with an increased risk of neonatal complications. A recent study of pregnancy outcomes in women with allograft RVOT conduits identified severe pulmonary regurgitation as a risk factor for neonatal complications, in particular preterm delivery.[15](#jah34058-bib-0015){ref-type="ref"} In contrast, we did not observe any difference in the incidence of neonatal events based on the severity of the maternal RVOT lesion. A possible explanation for the discordant findings might lie in the population demographics: We studied patients with isolated RVOT lesions while excluding those with significant left heart disease, while 30% of their patients in the Romeo et al study had primary aortic valve disease and received RVOT allograft conduits as a component of the Ross operation; only 4 patients with TOF--pulmonary atresia were included. Some authors have proposed abnormal maternal hemodynamics with resultant placental insufficiency as the pathophysiologic mechanism for prematurity and small‐for‐gestational‐age deliveries in patients with congenital heart disease.[4](#jah34058-bib-0004){ref-type="ref"}, [13](#jah34058-bib-0013){ref-type="ref"}, [23](#jah34058-bib-0023){ref-type="ref"} Patients with TOF--pulmonary atresia have abnormal pulmonary arterial architecture and often require multiple arterioplasties with prosthetic materials.[24](#jah34058-bib-0024){ref-type="ref"} It would seem reasonable to hypothesize abnormal pulmonary vascular function leading to suboptimal response to the obligatory increase in pulmonary blood flow during gestation, potentially resulting in placental insufficiency.

Limitations {#jah34058-sec-0020}
-----------

This is a retrospective single center study and is therefore prone to referral bias. The study population was relatively small, which limited our ability to perform multivariable analysis. In contrast to previous studies of pregnancy outcomes in congenital heart disease that enrolled patients with a wide spectrum of diagnoses, the current study focuses exclusively on a homogeneous subset of patients with isolated RVOT lesions, and this homogeneity increases the internal validity of our results. Another limitation was that we defined the hemodynamic significance of residual RVOT lesions based on quantitative and qualitative echocardiographic assessment without integrating invasive hemodynamic and cross‐sectional imaging data.

Conclusions {#jah34058-sec-0021}
-----------

In this study of patients with isolated RVOT lesions during pregnancy, we showed that the risk of cardiovascular complications was low, and that the severity of residual RVOT lesion was not associated with PRAO. Some of the patients with RVOT‐HS lesions who did not undergo surgical interventions tolerated subsequent pregnancies without either symptomatic or hemodynamic deterioration. Patients with TOF--pulmonary atresia appear to be at significantly higher risk for spontaneous abortions and neonatal complications. Further studies are required to explore the factors responsible for PRAO in patients with TOF--pulmonary atresia. Given that so many of the ACHD patients have isolated RVOT lesions, we hope that this study serves as a "pilot" for a larger, multicenter investigation.

Even within the context of the limitations of a retrospective study, our results suggest that the timing of surgical or transcatheter interventions should not be influenced by the anticipated effects of future pregnancy in these patients. These data are important for evidenced‐based counseling and clinical decision making in this subset of ACHD patients.
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